Table 2.
Vasopressor use and peripheral catheter data (n = 369).
| Variables | ||
|---|---|---|
| Vasopressor medication used | Dopamine | 32 (8.7%) |
| Epinephrine | 279 (75.6%) | |
| Norepinephrine | 42 (11.4%) | |
| Milrinone | 93 (25.2%) | |
| Maximum dose of vasopressor medication used (µg/kg/min) | Dopamine | 15 |
| Epinephrine | 0.25 | |
| Norepinephrine | 0.2 | |
| Milrinone | 0.8 | |
| Median duration of vasopressor medication used (hours) (IQR) | 24 (13–48) | |
| Vasopressor inotropic score | <5 | 147 (39.8%) |
| 5–10 | 167 (45.3%) | |
| 11–15 | 29 (7.9%) | |
| 16–20 | 20 (5.4%) | |
| >20 | 6 (1.6%) | |
| Vasopressor inotropic score (median; IQR) | 8 [5–10] | |
| Coadministration of vasopressor medication | 77 (20.9%) | |
| Size of peripheral IV catheter | 18 | 20 (5.4%) |
| 20 | 69 (18.7%) | |
| 22 | 101 (27.4%) | |
| 24 | 179 (48.5%) | |
| Conversion to central venous catheter (CVC) | 127 (34.4%) | |
| Reason for CVC conversion | Persistent high inotropic support | 30 (8.1%) |
| Difficulty to maintain PIV | 14 (3.8%) | |
| Persistent acidosis | 32 (8.7%) | |
| Need for multiple infusions | 6 (1.6%) | |
| Monitoring | 13 (3.5%) | |
| Unknown | 30 (8.1%) | |
| Time to CVC; hours (median; IQR) | 7 [5–12] | |
| Extravasation | 8 (2.2%) | |
IQR=interquartile range.